Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002453 · ClinicalTrials.gov registry record · NA

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

A NA study of HIV Infections, sponsored by Gilead Sciences.

Completed
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT00002453 is a NA study of HIV Infections that has completed, run by Gilead Sciences. The registered enrollment target is 300 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002453, a NA study of HIV Infections, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.

Conditions Studied

Interventions

  • DRUG Tenofovir disoproxil fumarate

Study Locations (1)

California

  • Tenofovir Coordinating Center - Foster City

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 1999-12
Phase NA

Sponsor

Gilead Sciences

504 total trials

What the Registry Record Tells You About NCT00002453

The ClinicalTrials.gov registry entry for NCT00002453 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir disoproxil fumarate is the first listed.

NCT00002453 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00002453 about?

NCT00002453 is a clinical study titled "A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection". This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.

What is the current status of trial NCT00002453?

This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 1999-12.

What conditions does trial NCT00002453 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002453?

The interventions under investigation include: Tenofovir disoproxil fumarate (DRUG).

Who is sponsoring clinical trial NCT00002453?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002453 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.